Loading...
Loading...
On
CNBC's Fast Money, Stephanie Link said that
Merck & Co., Inc.MRK posted a fine quarter although the company missed revenue expectations and it narrowed its full year forecast. The stock dropped 2.01 percent on Monday and Link thinks that profit taking is the reason for a decline. Given the run that
Merck had she wouldn't chase the stock.
Jim Lebenthal likes
Garmin Ltd.GRMN, which traded 2.44 percent higher on an upgrade by Goldman Sachs. He thinks that placing less emphasis on personal navigation and stepping into original equipment manufacturing for automobile and other sectors is good for the company.
Joe Terranova wouldn't buy
Sarepta Therapeutics IncSRPT after it dropped 32.47 percent on Monday. He added that it looks like its new drug application will be delayed for mid 2015.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in